Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 9901 participants.

Also called NCT01394952

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 9,901 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01394952
Other papers using this trial's data
  • Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis Diabetes care, 2023-05-01 DOI, PubMed 36897834
  • Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Lancet (London, England), 2019-07-13 DOI, PubMed 31189511
  • Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026-04 DOI, PubMed 41988866, PMC13084528 In the PMC Open Access subset under CC BY.
  • Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Lancet (London, England), 2019-07-13 DOI, PubMed 31189509
  • Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial The Lancet. Neurology, 2020-07 DOI, PubMed 32562683 PubMed links an erratum for this paper. Erratum: PMID 32949548
  • Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial The Journal of clinical endocrinology and metabolism, 2021-04-23 DOI, PubMed 33537745, PMC8063250 In the PMC Open Access subset under CC BY-NC-ND.
  • Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial The lancet. Diabetes & endocrinology, 2021-08 DOI, PubMed 34153269 PubMed links an erratum for this paper. Erratum: PMID 34298003
  • Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND Cardiovascular diabetology, 2021-09-25 DOI, PubMed 34563178, PMC8466679 In the PMC Open Access subset under CC BY.
  • Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial Scandinavian cardiovascular journal : SCJ, 2023-12 DOI, PubMed 36723445
  • HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial Diabetes care, 2022-03-01 DOI, PubMed 35043140, PMC8918189 In the PMC Open Access subset under a licence that is not Creative Commons.
  • The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial The lancet. Diabetes & endocrinology, 2020-02 DOI, PubMed 31924562
  • Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis Cardiovascular diabetology, 2020-11-25 DOI, PubMed 33239067, PMC7690176 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Germany, Hungary, Latvia, Lithuania, Mexico, New Zealand, Poland, Puerto Rico, Romania, Russia, South Africa, South Korea, Spain, Sweden, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01394952. Randomized; double masking; primary purpose treatment. Start 2011-07-22 (actual); primary completion 2018-08-21 (actual). Results posted on 2019-10-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Acronym
REWIND
Condition
Cardiovascular Disease
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01394952
Content hash
db4ffc0d064cf1828b95940a9d60e45549479085df376e13fb0f09a95cb9ed68